Nodal cytotoxic molecule (CM)-positive Epstein-Barr virus (EBV)-associated peripheral T cell lymphoma (PTCL): A clinicopathological study of 26 cases

Histopathology

Volumn 61, Issue 2, 2012, Pages 186-199

  Kato, Seiichi ^a   Takahashi, Emiko ^b   Asano, Naoko ^a   Tanaka, Tsutomu ^c   Megahed, Nirmeen ^a   Kinoshita, Tomohiro ^c   Nakamura, Shigeo ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cytotoxic molecule; Epstein Barr virus; Extranasal NK T cell lymphoma of nasal type; Not otherwise specified; Peripheral T cell lymphoma

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTOTOXIC FACTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; INTERNATIONAL PROGNOSTIC INDEX; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULE; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; RISK FACTOR; SYMPTOM; THROMBOCYTOPENIA; TUMOR VOLUME; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; LYMPHOMA, EXTRANODAL NK-T-CELL; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; PROGNOSIS; RNA, VIRAL; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

HUMAN HERPESVIRUS 4;

EID: 84864378115     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04199.x     Document Type: Article

References (54)

1. Vose JM, Armitage JO, Weisenburger DD et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes international T-cell lymphoma project. J. Clin. Oncol. 2008; 26; 4124-4130.
2. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma Study Group. Blood 1994; 84; 1361-1392.
3. Ichimura K, Kagami Y, Suzuki R et al. Phenotypic analysis of peripheral T/NK cell lymphoma: study of 408 Japanese cases with special reference to their anatomical states. Pathol. Int. 2003; 53; 333-344.
4. Swerdlow SH, Campo E, Harris NL eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008.
5. Jaffe ES, Krenacs L, Raffeld M. Classification of T-cell and NK-cell neoplasms based on the REAL classification. Ann. Oncol. 1997; 8(Suppl. 2); 17-24.
6. Kluin PM, Feller A, Gaulard P et al. Peripheral T/NK-cell lymphoma: a report of the IXth Workshop of the European Association for Haematopathology. Histopathology 2001; 38; 250-270.
7. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103; 2474-2479.
8. De Bruin PC, Kummer JA, Van der Valk P et al. Granzyme B expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization. Blood 1994; 84; 3785-3791.
9. Krenacs L, Smyth MJ, Bagdi E et al. The serine protease granzyme M is preferentially expressed in NK-cell, γδ T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood 2003; 101; 3590-3593.
10. Felgar RE, Macon WR, Kinney MC et al. TIA-1 expression in lymphoid neoplasms: identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am. J. Pathol. 1997; 150; 1893-1900.
11. Foss HD, Anagnostopoulos I, Araujo I et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996; 88; 4005-4011.
12. Yamashita Y, Yatabe Y, Tsuzuki T et al. Perforin and granzyme expression in cytotoxic T-cell lymphomas. Mod. Pathol. 1998; 11; 313-323.
13. Boulland ML, Kanavaros P, Wechsler J et al. Cytotoxic protein expression in natural killer cell lymphomas and in αβ and γδ peripheral T-cell lymphomas. J. Pathol. 1997; 183; 432-439.
14. Chan JK, Sin VC, Wong KF et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89; 4501-4513.
15. Chiang AK, Chan AC, Srivastava G et al. Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. Int. J. Cancer 1997; 73; 332-338.
16. Emile JF, Boulland ML, Haioun C et al. CD5- CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 1996; 87; 1466-1473.
17. Suzumiya J, Takeshita M, Kimura N et al. Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood 1994; 83; 2255-2260.
18. Belhadj K, Reyes F, Farcet JP et al. Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102; 4261-4269.
19. Cooke CB, Krenacs L, Stetler-Stevenson M et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta Tcell origin. Blood 1996; 88; 4265-4274.
20. Macon WR, Levy NB, Kurtin PJ et al. Hepatosplenic αβ T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic γδ Tcell lymphomas. Am. J. Surg. Pathol. 2001; 25; 285-296.
21. Salhany KE, Feldman M, Kahn MJ et al. Hepatosplenic gammadelta T-cell lymphoma: ultrastractural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation. Hum. Pathol. 1997; 28; 674-685.
22. Chott A, Haedicke W, Mosberger I et al. Most CD56+ intestinal lymphomas are CD8+ CD5- T-cell lymphomas of monomorphic small to medium size histology. Am. J. Pathol. 1998; 153; 1483-1490.
23. Daum S, Foss HD, Anagnostopoulos I et al. Expression of cytotoxic molecules in intestinal T-cell lymphomas: the German Study Group on Intestinal Non-Hodgkin Lymphoma. J. Pathol. 1997; 182; 311-317.
24. Arnulf B, Copie-Bergman C, Delfau-Larue M-H et al. Nonhepatosplenic γδ T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 1998; 91; 1723-1731.
25. Bekkenk MW, Vermeer MH, Jansen PM et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003; 102; 2213-2219.
26. Berti E, Tomasini D, Vermeer MH et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am. J. Pathol. 1999; 155; 483-492.
27. Kamarashev J, Burg G, Mingari MC et al. Differential expression of cytotoxic molecules and killer cell inhibitory receptors in CD8+ and CD56+ cutaneous lymphomas. Am. J. Pathol. 2001; 158; 1593-1598.
28. Kumar S, Krenacs L, Medeiros J et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T-lymphocytes. Hum. Pathol. 1998; 29; 397-403.
29. Salhany KE, Macon WR, Choi JK et al. Subcutaneous panniculitis like Tcell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am. J. Surg. Pathol. 1998; 22; 881-893.
30. Santucci M, Pimpinelli N, Massi D et al. Cytotoxic/natural killer cell cutaneous lymphomas: report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003; 97; 610-627.
31. Toro JR, Beaty M, Sorbara L et al. γδ T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch. Dermatol. 2000; 136; 1024-1032.
32. Toro JR, Liewehr DJ, Pabby N et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101; 3407-3412.
33. Krenacs L, Wellmann A, Sorbara L et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. Blood 1997; 89; 980-989.
34. Asano N, Suzuki R, Kagami Y et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am. J. Surg. Pathol. 2005; 29; 1284-1293.
35. Iqbal J, Weisenburger DD, Greiner TC et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010; 115; 1026-1036.
36. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 2004; 350; 1328-1337.
37. Cohen JI. Epstein-Barr virus infection. N. Engl. J. Med. 2000; 343; 481-492.
38. Rooney CM, Rowe M, Wallace LE et al. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature 1985; 317; 629-631.
39. Kelly G, Bell A, Rickinson A et al. Epstein-Barr virus associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 2002; 8; 1098-1104.
40. Swinnen LJ. Overview of posttransplant B-cell lymphoproliferative disorders. Semin. Oncol. 1999; 26; 21-25.
41. Kuze T, Nakamura N, Hashimoto Y et al. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn. J. Cancer Res. 2000; 91; 1233-1240.
42. Young LS, Rickinson AB. Epstein-Barr virus: 40years on. Nat. Rev. Cancer 2004; 4; 757-768.
43. Takahashi E, Asano N, C Li et al. Nodal T/NK-cell lymphoma of nasal type: a clinicopathological study of six cases. Histopathology 2008; 52; 585-596.
44. Brousset P, Butet V, Chittal S et al. Comparison of in situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohistochemical correlation with anti-latent membrane protein antibody. Lab. Invest. 1992; 67; 457-464.
45. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasal type. In Swerdlow SH, Campo E, Harris NL eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008; 285-288.
46. Ng SB, Lai KW, Murugaya S et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod. Pathol. 2004; 17; 1097-1107.
47. Dupis J, Emile JF, Mounier N et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006; 108; 4163-4169.
48. Went P, Agostinelli C, Gallamini A et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J. Clin. Oncol. 2006; 24; 2472-2479.
49. Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113; 3931-3937.
50. Gutiérrez-García G, García-Herrera A, Cardesa T et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann. Oncol. 2011; 22; 397-404.
51. Vose JM et al. International Peripheral T-cell Lymphoma (PTCL) Clinical and Pathology Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood (ASH Annual Meeting Abstracts) 2005; 106; 811.
52. Ballester B, Ramuz O, Gisselbrecht C et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006; 25; 1560-1570.
53. Cuadros M, Dave SS, Jaffe ES et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J. Clin. Oncol. 2007; 25; 3321-3329.
54. Nakamura S, Koshikawa T, Koike K et al. Phenotypic analysis of peripheral T cell lymphoma among the Japanese. Acta Pathol. Jpn. 1993; 43; 396-412.